[Application of sandostatin in malignant bowel obstruction].
OBJECTIVE
To investigate the effects of sandostatin in the treatment of malignant bowel obstruction(MBO).


METHODS
The data of 51 patients with MBO from Aug. 1996 to June. 2004 were analyzed retrospectively. All the patients were divided into two groups: routine treatment group (n=19) and sandostatin combined with routine treatment group (n=32). Symptoms, gastrointestinal secretions, nasogastric tube(NGT) removing and effects of sandostatin on different obstructive location were observed.


RESULTS
The symptom improvement in sandostatin group was 20/32 (63.1%) which was significantly higher than 4/19 (21.1%) in routine treatment group (P< 0.01). The average G-I secretion was (398 +/- 152) ml and (834 +/- 306) ml in sandostatin and traditional group respectively and the difference was significant (P< 0.05). No severe side and toxic effects were found during therapy.


CONCLUSIONS
Sandostatin can effectively relieve clinical symptoms and improve life quality in the bowel obstruction cases with advanced cancers.
Li
Jian
J
Department of Digestive Disease, Peking University, School of Oncology, Beijing Cancer Hospital, Beijing Institute for Cancer Research, Beijing 100036, China.
Jing
Mao-lin
ML
Shen
Lin
L
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007415:Intestinal Obstruction / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D011379:Prognosis; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
D015282:Octreotide